Remission in inflammatory arthritis: A new immunological target

Immunotherapy

Volumn 3, Issue 4, 2011, Pages 459-463

  Saleem, Benazir ^a   Walsh, Ceara A E ^a   Emery, Paul ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

anti TNF therapy; biologics; methotrexate; remission; rheumatoid arthritis; T cell

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 17; INTERLEUKIN 6 RECEPTOR ANTIBODY; METHOTREXATE; NATURAL KILLER CELL RECEPTOR NKG2A; RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTHRITIS; CELLULAR IMMUNITY; DRUG WITHDRAWAL; EDITORIAL; IMMUNOPATHOGENESIS; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; NATURAL KILLER T CELL; NOMENCLATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REMISSION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHOTREXATE; REMISSION INDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953807836     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.12     Document Type: Editorial

References (25)

1. Badley EM, Webster GK, Rasooly I: The impact of musculoskeletal disorders in the population: are they just aches and pains? Findings from the 1990 Ontario Health Survey. J. Rheumatol. 22(4), 733-739 (1995).
2. Emery P, Salmon M: Early rheumatoid arthritis: time to aim for remission? Ann. Rheum. Dis. 54(12), 944-947 (1995).
3. Smolen JS, Aletaha D, Bijlsma JW et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69(4), 631-637).
4. Emery P: The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy. J. Rheumatol. 24(7), 1436-1442 (1997).
5. Kroot EJ, de Jong BA, van Leeuwen MA et al.: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 43(8), 1831-1835 (2000).
6. Cope AP: T cells in rheumatoid arthritis. Arthritis Res. Ther. 10(Suppl. 1), S1 (2008).
7. Dalbeth N, Smith T, Gray S et al.: Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann. Rheum. Dis. 68(2), 279-282 (2009).
8. + T lymphocytes in psoriatic arthritis. J. Rheumatol. 26(5), 1117-1124 (1999).
9. Ponchel F, Morgan AW, Bingham SJ et al.: Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 100(13), 4550-4556 (2002).
10. Koenders MI, Lubberts E, Oppers-Walgreen B et al.: Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 167(1), 141-149 (2005).
11. Moran EM, Mullan R, McCormick J et al.: Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies. Arthritis Res. Ther. 11(4), R113 (2009).
12. van den Berg WB, Miossec P: IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5(10), 549-553 (2009).
13. Korn T, Reddy J, Gao W et al.: Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13(4), 423-431 (2007).
14. Burgoyne CH, Field SL, Brown AK et al.: Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Ann. Rheum. Dis. 67(6), 750-757 (2008).
15. van Dongen H, van Aken J, Lard LR et al.: Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56(5), 1424-1432 (2007).
16. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
17. Saleem B, Keen H, Goeb V et al.: Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann. Rheum. Dis. 69(9), 1636-1642 (2010).
18. Mierau M, Schoels M, Gonda G, Fuchs J, Aletaha D, Smolen JS: Assessing remission in clinical practice. Rheumatology (Oxford), 46(6), 975-979 (2007).
19. Brown AK, Conaghan PG, Karim Z et al.: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 58(10), 2958-2967 (2008).
20. Saleem B, Brown AK, Keen H et al.: Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum. 60(7), 1915-1922 (2009).
21. Wakefield RJ, Freeston JE, Hensor EM, Bryer D, Quinn MA, Emery P: Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. Arthritis Rheum. 57(8), 1564-1567 (2007).
22. Cuthbert R, Parmar R, Nam J et al.: Dys-regulation of T-cell subsets and cytokines is associated with the development of inflammatory symptoms in ACPA-positive asymptomatic individuals. Arthritis Rheum. 62(Suppl. 10) S455 (2010).
23. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al.: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Internal Med. 146(6), 406-415 (2007).
24. Buch MH, Marzo-Ortega H, Bingham SJ, Emery P: Long-term treatment of rheumatoid arthritis with tumour necrosis factor a blockade: outcome of ceasing and restarting biologicals. Rheumatology (Oxford), 43(2), 243-244 (2004).
25. Walsh C, Veale D, Fitzgerald O, Fearon U, Bresnihan B: Withdrawal of anti-TNF therapy in patients with rheumatoid arthritis in clinical remission: can maintenance of remission be predicted? Arthritis Rheum. 59(9), S480 (2007).